BCL2 and diffuse large B-cell lymphoma: In this study, we investigated the prognostic significance of Bcl-2 protein expression on response to existing rituximab-based immunochemotherapy regimens and its influence on both five-year overall and progression-free survival in non-GCB DLBCL, of which it was highly expressed in 72.2% of cases (Table 1).